Bayer AG’s long-acting treatment for hemophilia A won a recommendation from a European Medicines Agency (EMA) panel for the treatment of the rare genetic disorder in which blood does not clot easily.
A European Medicines Agency panel recommended the approval of U.S. pharmaceutical group Eli Lilly’s migraine treatment, bringing the drug one step closer to being sold in the European Union.
Takeda Pharmaceutical Co.’s lung cancer drug Alunbrig received the recommendation of a European Union panel, more than a year after winning U.S. regulatory approval.
A European Medicines Agency panel recommended approval of Spark Therapeutics’ gene therapy Luxturna for blindness, a move that also boosts Swiss drugmaker Novartis that bought the rights to one of the world’s costliest treatments outside the United States.
The French drugmaker Sanofi secured approval in Europe for a rare blood-clotting disorder treatment using nanobodies.
Novartis’ generics unit won a European panel’s recommendation for its biosimilar version of AbbVie’s Humira as the Swiss drugmaker aims to take a bite out of sales of the world’s best-selling medicine.
Novartis’ new migraine drug Aimovig won a key recommendation from a key European panel on Friday, helping open the way for potential sales before the end of the year for a medicine the Swiss drugmaker is counting on to boost growth.
Gilead Sciences Inc.’s three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency.
A panel of European Medicines Agency recommended against granting marketing approval to Portola Pharmaceuticals Inc.’s oral blood thinner, saying the benefits of the drug did not outweigh risks.
A panel of European Medicines Agency recommended approval for GlaxoSmithKline’s two-drug regimen to treat HIV, the virus that causes AIDS.